N/A
Manufactured by BM Private Limited
6 FDA adverse event reports analyzed
Last updated: 2026-04-15
THUJA OCCIDENTALIS is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by BM Private Limited. The most commonly reported adverse reactions for THUJA OCCIDENTALIS include AGRANULOCYTOSIS, DRUG INEFFECTIVE, FLATULENCE, HAEMATOCHEZIA, IRRITABILITY. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for THUJA OCCIDENTALIS.
Out of 4 classified reports for THUJA OCCIDENTALIS:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 6 FDA FAERS reports that mention THUJA OCCIDENTALIS. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include AGRANULOCYTOSIS, DRUG INEFFECTIVE, FLATULENCE, HAEMATOCHEZIA, IRRITABILITY, TREATMENT FAILURE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list BM Private Limited in connection with THUJA OCCIDENTALIS. Always verify the specific product and NDC with your pharmacist.